Research programme: cannabinoids - PreveCeutical Medical/UniQuest

Drug Profile

Research programme: cannabinoids - PreveCeutical Medical/UniQuest

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PreveCeutical Medical; UniQuest
  • Class Anti-inflammatories; Cannabinoids; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammation; Neurological disorders; Pain; Seizures

Most Recent Events

  • 22 Apr 2017 PreveCeutical Medical enters into a research and development agreement with UniQuest for sol-gel based cannabinoid therapeutics
  • 14 Apr 2017 Early research in Inflammation in Canada (Intranasal)
  • 14 Apr 2017 Early research in Neurological disorders in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top